MindWalk Holdings Corp.(HYFT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.99
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HYFT

11/13/2026: HYFT (1-star) is currently NOT-A-BUY. Pass it for now.

MindWalk Holdings Corp. is a micro-cap bio-native AI and life sciences company that leverages its proprietary HYFT and LensAI platforms alongside full-stack wet-lab capabilities to accelerate antibody discovery. The company's core strengths lie in its differentiated computational language models and established enterprise partnerships with major global pharmaceutical clients. Its primary growth story centers on capitalizing on the increasing adoption of generative AI within drug development pipelines. However, key risks include ongoing net operating losses, micro-cap share volatility, and intense competition in the TechBio sector. The stock suits risk-tolerant growth or momentum investors seeking exposure to computational biology, requiring close monitoring of partnership contract wins and cash-burn metrics.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile operating in a high-growth TechBio sector, its micro-cap size and early-stage scaling introduce execution uncertainties.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp volume-driven rallies upon major commercial partnership or platform milestone announcements.
Value investorWeak fitThe company lacks current profitability and positive earnings multiples, making it unsuitable for traditional value metrics.
Dividend investorWeak fitMindWalk does not pay dividends, directing all available capital into technology development and operations.
Low-risk investorWeak fitHigh share price volatility, micro-cap liquidity profile, and negative net income create substantial risk exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock exhibits wide price swings and high beta, typical of micro-cap technology equities.
Valuation riskMedium / highValuation is heavily dependent on future software adoption and speculative platform growth projections.
Competition risk (AI platform competition)HighThe company competes with heavily funded AI drug discovery firms and internal pharmaceutical R&D initiatives.
Business qualityMediumProprietary technology provides strong scientific differentiation, but ongoing losses weigh on near-term financial quality.
Dividend incomeLow / noneNo payouts are distributed to investors, eliminating dividend income generation.
Execution riskHighSuccess relies heavily on scaling platform contracts and translating computational insights into commercial milestones.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 47.10M USD
Price to earnings Ratio -
1Y Target Price 4.33
Price to earnings Ratio -
1Y Target Price 4.33
Volume (30-day avg) 326.0K shares
Beta 0.78
52 Weeks Range 0.91 - 2.99
Updated Date 11/15/2026
52 Weeks Range 0.91 - 2.99
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.26

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 105.12%
Avg. Invested days 18
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HYFT receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
HYFT has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and moderate ownership. In FY2026 versus FY2025, strong earnings growth (+54.6%) is partially offset by weak cash generation (FCF margin -82.7%), negative revenue growth (-37.5%), weak profitability (net margin -89.7%).

Financial Health Rating

★★★★★
HYFT's financial health is soft, with the relatively strongest area being solid liquidity, including working-capital and asset support (WC/assets 48.9%). Profitability is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is HYFT's strongest growth driver at +54.6% FY2026 versus FY2025 (strong, 5 stars). By comparison, while revenue growth (-37.5%, negative) and free-cash-flow growth (-75.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 9.1% (soft) and 89.7% of outstanding shares are publicly tradable (strong). Insider ownership of 9.25% supports management-shareholder alignment.

Top 5 Institutional Investors

Ingalls & Snyder LLC 6.38%
Susquehanna International Group, LLP 1.09%
Renaissance Technologies Corp 0.37%
BlackRock Inc 0.32%
Marshall Wace Asset Management Ltd 0.29%

Unit Economics (Per $1K Revenue)

★★★★★
HYFT generates approximately $588 of gross profit, $-960 of operating income, and $-827 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 2.89%

Quantitative Style Profile

★★★★★
HYFT has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
AI Platforms and Software LicensingLicensing proprietary tools like LensAI and HYFT to pharmaceutical partners for data analysis and target discovery.Generates high-margin recurring or project-based technology access fees from drug developers.
Contract Research ServicesProviding custom wet-lab antibody discovery, characterization, and validation services.Serves as a reliable baseline service revenue stream while closing the loop for AI-discovered candidates.
Geography (North America & International)Service delivery and licensing contracts spanning the United States, Europe, Canada, and Australia.Diversifies commercial exposure across major global biotech and pharma hubs.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 46.10M
Price to Sales(TTM) 2.9
Enterprise Value 46.10M
Price to Sales(TTM) 2.9
Enterprise Value to Revenue 4.05
Enterprise Value to EBITDA -4.68
Shares Outstanding 47.57M
Shares Floating 42.69M
Shares Outstanding 47.57M
Shares Floating 42.69M
Percent Insiders 9.25
Percent Institutions 9.08

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.